KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.

Rongbo Lin, Lang He, Mingqian Lu, Li Zhuang, Wei Lu, Yunfang Chen, Junli Liu, Shaowei Lin, Shen Zhao, Liyu Su, Xia Lv, Jincai Zhong, Zhichun Zhang, Liyan Gong, Yushuang Luo, Tao Ren, Lei Cao, Jiang Liu, Huichao Zou, Chunxiang Shang, Lichun Cui, Shaojun Chen, Shuqiang Wu, Shanlan Yang, Xiaojuan Zhang, Pengtao Chen, Hong Deng, Yongsheng Zhao, Feng Fu, Bisheng Zhu, Xiaodong Wu, Yiming Bi, Hanxiang An, Tao Sun, Hong Gao, Zhongchao Huo, Jun Liang, Ying Chen, Cheng Huang

J Natl Compr Canc Netw 24(6) 257-264

PMID42119607
PMCID-
DOI10.6004/jnccn.2025.7476
发表日期2026-05-12
入排依据:This is an original Phase III randomized trial in human oncology patients with a drug intervention, but its primary efficacy endpoint is a pain score (NRS), not a time-to-event outcome like OS, PFS, or DFS. There is no mention of Kaplan-Meier analysis or hazard ratios for such endpoints.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Effective management of severe cancer pain remains challenging. Our phase II study suggested that intravenous patient-controlled analgesia with hydromorphone (IPCA-HM), delivered either as bolus-only or continuous infusion, is superior to oral morphine for patients with severe cancer pain, with bolus-only potentially providing comparable efficacy to infusion while resulting in a lower rate of morphine equivalent dose (MED) escalation. This phase III study aimed to validate these findings. PATIENTS AND METHODS: Patients with solid tumors and severe cancer pain (≥7 at rest on an 11-point Numeric Rating Scale [NRS]) who achieved successful 24-hour IPCA-HM dose-finding were randomized (2:2:1) to bolus-only IPCA-HM (bolus), continuous infusion IPCA-HM (infusion), or oral morphine (oral) for 6 days. The primary outcome was average NRS score over days 1-3 (3DNRS). RESULTS: Of 1,349 patients from 48 oncology centers, 542 received bolus, 540 infusion, and 267 oral. Mean [SD] 3DNRS scores were 2.36 [0.89], 2.26 [0.87], and 2.94 [1.16], respectively. Both IPCA-HM arms were statistically significantly better than the oral arm in 3DNRS scores (bolus vs oral: mean difference, 0.58 [95% CI, 0.42 to 0.74]; infusion vs oral: 0.68 [95% CI, 0.52 to 0.84]; both P<.001). Bolus was noninferior to infusion (mean difference, 0.10 [95% CI, -0.01 to 0.20]; predefined noninferiority margin, 0.3; P<.001), achieving noninferiority in opioid-naïve, but not opioid-tolerant, patients. Median (IQR) total MEDs over days 1-6 were 400 (260-692) mg, 643 (380-1,117) mg, and 867 (540-1,313) mg for the bolus, infusion, and oral arms, respectively. Opioid-related adverse events (all grade 1 or 2) were comparable between the bolus (20.1%) and infusion (23.0%) arms, and both were lower than in the oral arm (33.7%). CONCLUSIONS: For severe cancer pain, both IPCA-HM regimens provided statistically significantly better pain relief compared with oral morphine. The bolus regimen achieved noninferior efficacy compared with infusion while requiring lower opioid doses, providing a safe and effective analgesic option.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。